Micardis®. Observational Study in Patients With Essential Hypertension

Micardis®. Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02200094

Enrollment

4532

Registered

2014-07-25

Start date

1999-12-31

Completion date

Unknown

Last updated

2014-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.

Interventions

DRUGLow dose of Telmisartan, once daily

DRUGHigh dose of Telmisartan, once daily

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients of either sex over the age of 18 years suffering from essential hypertension requiring treatment according to the physician

Exclusion criteria

* Hypersensitivity to the active component or to any of the excipients * Pregnancy and lactation * Biliary obstructive disorders * Severe hepatic impairment * Severe renal impairment

Design outcomes

Primary

Measure	Time frame
Changes in systolic and diastolic blood pressure	Baseline, 4 weeks and 3 months after start of treatment
Percentage of patients with dose titration to 80 mg	4 weeks and 3 months after start of treatment
Number of patients with adverse events	Up to 3 months after start of treatment
Global evaluation of treatment compliance by investigator, a 6-point rating scale	4 weeks and 3 months after start of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026